An increased proportion of patients with both intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL) was observed in Infasurf-treated infants in the Infasurf- Exosurf
Neonatal controlled trials.
A 1991 paper by Dechant and Faulds noted that in a large clinical trial, babies diagnosed with respiratory distress syndrome who were treated with Exosurf had fewer pneumothoraces, and survivors had less incidence of bronchopulmonary dysplasia.
Although Exosurf was one of the important early protein-free non-biological surfactant preparations of the 1980s, it was later withdrawn from the U.
Four large (several hundred in each group), prospective randomized clinical trials comparing Exosurf
(synthetic, no apoproteins) to Survanta (beractant) and to Infasurf (calfactant) have been conducted.
His involvement in successful marketed products includes Lamictal (Epilepsy), Zomig (Migraine), Malarone (PCP/Malaria), Atracurium (NMB), Wellbutrin (Anti-depressant/Smoking Cessation) and Exosurf
Within 30 minutes of birth, infants in the study received SURFAXIN, Exosurf
(colfosceril palmitate) or Survanta[R] (beractant).
(colfosceril palmitate), which was the only synthetic surfactant on the market, has been removed.
Exosurf, although the first approved synthetic surfactant, lacks any surfactant proteins, most noticeably protein SP-B.
President and Chief Executive Officer of Discovery stated, "We are convinced of the inherent pharmacology of Surfaxin and its superior profile compared to Exosurf and that the key to success is high quality execution.
Of the total, 623 infants were randomly assigned to receive an air placebo and 614 were randomly assigned to two intratracheal installations of Exosurf
Beginning in July 1989, the company provided Exosurf
Neonatal (colfosceril palmitate/celyl alcohol/Lyloxapol), free of charge, to more than 11,000 premature infants with respiratory distress syndrome.